De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Nuvalent Beheer

Beheer criteriumcontroles 3/4

De CEO Nuvalent's is Jim Porter, benoemd in Feb2020, heeft een ambtstermijn van 4.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.38M, bestaande uit 6.4% salaris en 93.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde $ 7.70M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 3.8 jaar.

Belangrijke informatie

Jim Porter

Algemeen directeur

US$9.4m

Totale compensatie

Percentage CEO-salaris	6.4%
Dienstverband CEO	4.7yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	3.8yrs

Recente managementupdates

Recent updates

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Apr 22

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Feb 26

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Jan 07

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Sep 23

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Jun 10

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Feb 24

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Sep 13

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Aug 10

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

May 28

We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely

Oct 29

Analyse CEO-vergoeding

Hoe is Jim Porter's beloning veranderd ten opzichte van Nuvalent's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$174m
Mar 31 2024	n/a	n/a	-US$146m
Dec 31 2023	US$9m	US$603k	-US$126m
Sep 30 2023	n/a	n/a	-US$114m
Jun 30 2023	n/a	n/a	-US$100m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$5m	US$580k	-US$82m
Sep 30 2022	n/a	n/a	-US$73m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$57m
Dec 31 2021	US$5m	US$424k	-US$46m
Sep 30 2021	n/a	n/a	-US$36m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$759k	US$335k	-US$15m

Compensatie versus markt: De totale vergoeding ($USD 9.38M ) Jim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).

Compensatie versus inkomsten: De vergoeding van Jim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jim Porter (48 yo)

4.7yrs

Tenure

US$9,376,872

Compensatie

Dr. James R. Porter, also known as Jim, Ph.D. has been Chief Executive Officer and President of Nuvalent, Inc. since February 1, 2020 and has been Director since February 2020. He joined Nuvalent during co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Porter	CEO, President & Director	4.7yrs	US$9.38m	0.11% $ 7.9m
Matthew Shair	Founder	7.7yrs	US$688.18k	2.34% $ 173.3m
Alexandra Balcom	CFO & Treasurer	3.8yrs	US$3.54m	0.047% $ 3.5m
Christopher Turner	Chief Medical Officer	3.6yrs	US$3.60m	0.021% $ 1.5m
Benjamin Lane	Senior Vice President of Technical Operations	2.3yrs	geen gegevens	geen gegevens
Henry Pelish	Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Deborah Miller	Chief Legal Officer & Secretary	3.3yrs	US$1.69m	0.047% $ 3.5m
Matthew Metivier	Senior Vice President of Human Resources	2.6yrs	geen gegevens	geen gegevens
Darlene Noci	Chief Development Officer	3.8yrs	geen gegevens	0.047% $ 3.5m
John Soglia	Senior Vice President of Translational Development	1.7yrs	geen gegevens	geen gegevens
Perrin Wilson	Senior Vice President of Business Development & Strategy	1.1yrs	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

48yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NUVL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Porter	CEO, President & Director	4.7yrs	US$9.38m	0.11% $ 7.9m
Matthew Shair	Founder	7.7yrs	US$688.18k	2.34% $ 173.3m
Sapna Srivastava	Independent Non-Executive Director	3.3yrs	US$503.18k	0% $ 0
Anna Protopapas	Independent Chairman	2.6yrs	US$523.18k	0% $ 0
Pasi Antero Janne	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
D. Gilliland	Independent Non-Executive Director	3.8yrs	US$495.68k	0% $ 0
Michael Meyers	Member of Scientific Advisory Board & Independent Director	2yrs	US$494.36k	0% $ 0
Cameron Wheeler	Independent Non-Executive Director	7.7yrs	US$499.45k	geen gegevens
Joseph Pearlberg	Independent Non-Executive Director	3.8yrs	US$494.00k	geen gegevens
Emily Conley	Independent Director	2.7yrs	US$495.90k	0.000010% $ 740.3
D. Camidge	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Aaron Hata	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NUVL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Nuvalent Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CFO & Treasurer notifies of intention to sell stock

CFO & Treasurer exercised options and sold US$564k worth of stock

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Recent updates

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Nuvalent: Likely Approvals Coming Up Do Not Justify This Valuation

Nuvalent, Inc. has completed a Follow-on Equity Offering in the amount of $500 million.

Price target increased by 8.1% to US$111

Nuvalent, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

Nuvalent, Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of Alk-Selective Inhibitor Nvl-655

CFO & Treasurer exercised options and sold US$564k worth of stock

New major risk - Revenue and earnings growth

Nuvalent (NASDAQ:NUVL) Is In A Strong Position To Grow Its Business

CFO & Treasurer exercised options and sold US$517k worth of stock

Nuvalent, Inc. Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

Nuvalent, Inc. Announces Promotion of Henry Pelish to Chief Scientific Officer

CFO & Treasurer notifies of intention to sell stock

Nuvalent: Making Precise Progress In Its Oncology Pipeline

Independent Director notifies of intention to sell stock

Nuvalent: NVL-655 Could Bring Blockbuster Potential

Chief Legal Officer & Secretary exercised options and sold US$528k worth of stock

Nuvalent, Inc. Receives U.S. FDA Breakthrough Therapy Designation for NVL-655

Nuvalent, Inc., Annual General Meeting, Jun 12, 2024

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Price target increased by 10% to US$102

Independent Director notifies of intention to sell stock

Price target increased by 8.6% to US$92.13

Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024

Price target increased by 7.4% to US$84.83

Nuvalent, Inc. Initiates the Phase 2 Portion of Alkove-1 Clinical Trial for Patients with Alk-Positive Nsclc and Other Solid Tumors

Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?

Chief Development Officer notifies of intention to sell stock

Founder notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

New minor risk - Share price stability

Price target increased by 11% to US$59.14

Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with Ros1-Positive NSCLC and Other Solid Tumors

New major risk - Revenue and earnings growth

Price target increased by 8.7% to US$50.83

Chief Legal Officer & Secretary notifies of intention to sell stock

Price target increased by 8.7% to US$50.80

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer notifies of intention to sell stock

Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Chief Development Officer exercised options and sold US$125k worth of stock

Price target increased by 10% to US$46.75

Chief Development Officer exercised options and sold US$113k worth of stock

Chief Development Officer exercised options and sold US$77k worth of stock

Chief Development Officer exercised options and sold US$86k worth of stock

We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow

Chief Legal Officer & Secretary notifies of intention to sell stock

Chief Development Officer exercised options and sold US$85k worth of stock

Chief Legal Officer & Secretary exercised options and sold US$51k worth of stock

Chief Development Officer exercised options and sold US$121k worth of stock

Nuvalent Inc. Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

Chief Development Officer exercised options and sold US$130k worth of stock

Price target increased to US$43.67

High number of new directors

Chief Legal Officer & Secretary exercised options and sold US$287k worth of stock

Nuvalent, Inc. Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients withROS1-Positive NSCLC

Chief Development Officer exercised options and sold US$85k worth of stock

Nuvalent, Inc. Currently Enrolling Patients in the Phase 1 Portion of Its Arros-1 Study, A Phase 1/2 Clinical Trial

Chief Development Officer exercised options and sold US$72k worth of stock

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Nuvalent, Inc. Present Preliminary Phase 1 Data from ARROS-1 Clinical Trial of NVL-520 at 34th EORTC-NCI-AACR Symposium and Announces Pipeline Updates

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent, Inc. Presents New Preclinical Data Supporting Potential Best-In-Class Profile for ALK-Selective Inhibitor NV-655 At IASLC 2022 World Conference on Lung Cancer Annual Meeting

Nuvalent, Inc. Announces Leadership Promotions

Insider exercised options and sold US$278k worth of stock